Compare Heron Therapeutics Inc (HRTX) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Invesco S&P 500 Low Volatility ETF trades at $75.99. The key difference: Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | SPLV | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | — |
52-Week High | $1.96 | $77.45 |
52-Week Low | $0.39 | $70.30 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
SPLV trades at $76.09, down 0.63% today, with a bullish technical outlook supported by moving averages and key support at $76. The ETF focuses on low-volatility S&P 500 stocks, offering stability amid market uncertainty, with recent news highlighting its defensive appeal during tech sell-offs and geopolitical tensions. Dividend distributions are scheduled for mid-2026 at $0.14 per share.
Outlook remains positive for risk-averse investors seeking equity exposure with reduced volatility, though reliance on market sentiment and interest rate trends poses risks. The ETF's strategy aligns with current defensive positioning, but limited growth potential may cap upside compared to broader market indices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
